BCL2L1 and glioblastoma: In fact, they revealed that targeting the aberrant splicing of Bcl-xL, using specific SSOs (named Bclx-vMO), was able to reduce Bcl-xL, increase Bcl-xS, and enhance the radiosensitivity of GBM cells.